세계의 면역조절제 시장 보고서(2025년)

An immunomodulator is a substance or medication utilized to modify or regulate the activity of the immune system, often employed in the treatment of various medical conditions. The specific application of immunomodulators varies depending on the underlying condition being addressed and the desired effect on immune response.

The primary product categories within the immunomodulator market comprise immunosuppressants, immunostimulants, and other product types. Immunosuppressants are medications designed to weaken the body's immune system, thereby reducing its capacity to combat diseases and foreign substances. These products are distributed through channels including hospital pharmacies, online pharmacies, retail pharmacies, and other distribution channels. They find application across various medical fields such as oncology, respiratory diseases, human immunodeficiency virus (HIV), among others, and are utilized by a range of end-users including hospitals, clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The immunomodulator market research report is one of a series of new reports from The Business Research Company that provides immunomodulator market statistics, including immunomodulator industry global market size, regional shares, competitors with an immunomodulator market share, detailed immunomodulator market segments, market trends, and opportunities, and any further data you may need to thrive in the immunomodulator industry. This immunomodulator research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunomodulator market size has grown strongly in recent years. It will grow from $219.94 billion in 2024 to $237.02 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to healthcare infrastructure development, increased awareness among patients, the aging population, increasing incidence of autoimmune diseases, and the introduction of biologic drugs.

The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $311.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing patient preference for non-invasive, regulatory approvals and guidelines, the extent of health insurance coverage for immunomodulatory treatments, the number and progress of immunomodulatory drugs, and government healthcare expenditure. Major trends in the forecast period include advancements in biotechnology and immunotherapy, the number and progress of immunomodulatory drugs in the research and development pipeline, advances in technology, the trend towards personalized medicine, and advancements in immuno-oncology.

The forecast of 7.1% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced immunotherapies by inflating prices of JAK inhibitors and interleukin blockers developed in Switzerland and the UK, resulting in delayed autoimmune disease management and higher rheumatology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic diseases is anticipated to significantly drive the growth of the immunomodulator market in the coming years. Chronic diseases are long-term medical conditions that develop gradually and persist for extended periods, often for a lifetime. The rise in chronic diseases is fueled by factors such as an aging population, lifestyle choices, genetic predispositions, and the availability and infrastructure of healthcare systems. Immunomodulators play a crucial role in managing chronic diseases by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom control. For instance, in September 2023, the World Health Organization (WHO) reported that 41 million deaths, accounting for 74% of all global deaths, were attributed to non-communicable diseases (NCDs) or chronic diseases. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the growing burden of chronic diseases is driving the demand for immunomodulators.

Companies in the immunomodulator market are increasingly focusing on developing non-immunosuppressive products to meet the rising demand for treatments that modulate immune responses without compromising overall immune function. Non-immunosuppressive treatments do not suppress or weaken the immune system. For example, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, commenced early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is designed to treat patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089's development in treating bullous pemphigoid. This innovative, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to activate an endogenous regulatory mechanism that mitigates autoimmune dysregulation. The primary objective of the study is to evaluate the safety and tolerability of NVG-2089, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics.

In February 2022, Equillium, Inc., a US-based biotechnology company, acquired Bioniz Therapeutics Inc. for an undisclosed amount. This acquisition significantly expanded Equillium's immunology pipeline by incorporating two first-in-class clinical-stage assets and a proprietary product discovery platform. Bioniz Therapeutics Inc., a US-based company, develops cytokine-targeted medicines for treating immuno-inflammatory disorders and cancer, which are part of the immunomodulator category. This acquisition underscores the strategic importance of expanding product portfolios to include innovative immunomodulatory treatments.

Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.

North America was the largest region in the immunomodulator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immunomodulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunomodulator market consists of sales of herbal immunomodulators, vaccines, immunomodulatory drugs, monoclonal antibodies, and interferons. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunomodulator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunomodulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunomodulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunomodulator market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Immunosuppressants; Immunostimulants; Other Product Types
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Oncology; Respiratory; Human Immunodeficiency Virus; Other Applications
• 4) By End-User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Immunosuppressants: Corticosteroids; Calcineurin Inhibitors (Tacrolimus, Cyclosporine); Mtor Inhibitors ( Sirolimus, Everolimus); Antimetabolites ( Azathioprine, Methotrexate); Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab); Janus Kinase (Jak) Inhibitors; T-Cell Inhibitors; Other Immunosuppressive Agents
• 2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins); Monoclonal Antibodies For Immune Stimulation; Vaccines ( Cancer Vaccines, Preventive Vaccines); Adjuvants And Immune Modulatory Agents; Immunostimulatory Agents For Autoimmune Diseases; Toll-Like Receptor (Tlr) Agonists; Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)
• 3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors); Small Molecule Immunomodulators; Immunotherapy Drugs; Stem Cell-Based Immunomodulators; Immuno-Oncology Drugs; Probiotics And Other Natural Immunomodulatory Agents
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Sanofi S.A; Bristol Myers Squibb Company; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Applied Molecular Genetics Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Vertex Pharmaceuticals Incorporated; UCB S.A.; Horizon Therapeutics plc; Incyte Corporation; Ipsen SA; Kyowa Kirin Co. Ltd.; Amicus Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunomodulator Market Characteristics

3. Immunomodulator Market Trends And Strategies

4. Immunomodulator Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Immunomodulator Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunomodulator PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunomodulator Market Growth Rate Analysis
• 5.4. Global Immunomodulator Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunomodulator Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunomodulator Total Addressable Market (TAM)

6. Immunomodulator Market Segmentation

• 6.1. Global Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Immunostimulants
• Other Product Types
• 6.2. Global Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Respiratory
• Human Immunodeficiency Virus
• Other Applications
• 6.4. Global Immunomodulator Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.5. Global Immunomodulator Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Calcineurin Inhibitors (Tacrolimus, Cyclosporine)
• MTOR Inhibitors (Sirolimus, Everolimus)
• Antimetabolites (Azathioprine, Methotrexate)
• Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab)
• Janus Kinase (JAK) Inhibitors
• T-Cell Inhibitors
• Other Immunosuppressive Agents
• 6.6. Global Immunomodulator Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokine And Growth Factor-Based Immunostimulants (Interferons, Interleukins)
• Monoclonal Antibodies For Immune Stimulation
• Vaccines (Cancer Vaccines, Preventive Vaccines)
• Adjuvants And Immune Modulatory Agents
• Immunostimulatory Agents For Autoimmune Diseases
• Toll-Like Receptor (TLR) Agonists
• Nucleic Acid-Based Immunostimulants (DNA Or RNA Vaccines)
• 6.7. Global Immunomodulator Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics (Fusion Proteins, Immune Checkpoint Inhibitors)
• Small Molecule Immunomodulators
• Immunotherapy Drugs
• Stem Cell-Based Immunomodulators
• Immuno-Oncology Drugs
• Probiotics And Other Natural Immunomodulatory Agents

7. Immunomodulator Market Regional And Country Analysis

• 7.1. Global Immunomodulator Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunomodulator Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunomodulator Market

• 8.1. Asia-Pacific Immunomodulator Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunomodulator Market

• 9.1. China Immunomodulator Market Overview
• 9.2. China Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunomodulator Market

• 10.1. India Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunomodulator Market

• 11.1. Japan Immunomodulator Market Overview
• 11.2. Japan Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunomodulator Market

• 12.1. Australia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunomodulator Market

• 13.1. Indonesia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunomodulator Market

• 14.1. South Korea Immunomodulator Market Overview
• 14.2. South Korea Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunomodulator Market

• 15.1. Western Europe Immunomodulator Market Overview
• 15.2. Western Europe Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunomodulator Market

• 16.1. UK Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunomodulator Market

• 17.1. Germany Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunomodulator Market

• 18.1. France Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunomodulator Market

• 19.1. Italy Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunomodulator Market

• 20.1. Spain Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunomodulator Market

• 21.1. Eastern Europe Immunomodulator Market Overview
• 21.2. Eastern Europe Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunomodulator Market

• 22.1. Russia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunomodulator Market

• 23.1. North America Immunomodulator Market Overview
• 23.2. North America Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunomodulator Market

• 24.1. USA Immunomodulator Market Overview
• 24.2. USA Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunomodulator Market

• 25.1. Canada Immunomodulator Market Overview
• 25.2. Canada Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunomodulator Market

• 26.1. South America Immunomodulator Market Overview
• 26.2. South America Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunomodulator Market

• 27.1. Brazil Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunomodulator Market

• 28.1. Middle East Immunomodulator Market Overview
• 28.2. Middle East Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunomodulator Market

• 29.1. Africa Immunomodulator Market Overview
• 29.2. Africa Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunomodulator Market Competitive Landscape And Company Profiles

• 30.1. Immunomodulator Market Competitive Landscape
• 30.2. Immunomodulator Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Immunomodulator Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Applied Molecular Genetics Inc.
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Biogen Inc.
• 31.14. Vertex Pharmaceuticals Incorporated
• 31.15. UCB S.A.

32. Global Immunomodulator Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunomodulator Market

34. Recent Developments In The Immunomodulator Market

35. Immunomodulator Market High Potential Countries, Segments and Strategies

• 35.1 Immunomodulator Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunomodulator Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunomodulator Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer